Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

26/11/2015 - 2 minutes

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease…

novonordisk_ablynxAblynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), Merck (in Neurology) and of course MSD (aka Merck & Co.).

Now their new collaboration with the Bagsværd based Novo Nordisk Giant will lead to a series of milestone related payments (though for what has not yet been disclosed!). First, a €5M upfront license fee will be paid, followed by a €4M/year for the initial 3 years of the research program.

In addition, Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to €182M per program plus tiered royalties on the annual net sales on any products resulting from the collaboration.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member